KESTRA MEDICAL TECHNOLOGIES (KMTS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:KMTS • BMG524411052

25.47 USD
+0.35 (+1.39%)
At close: Feb 6, 2026
25.47 USD
0 (0%)
After Hours: 2/6/2026, 4:30:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KMTS. KMTS was compared to 186 industry peers in the Health Care Equipment & Supplies industry. KMTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KMTS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • KMTS had negative earnings in the past year.
  • KMTS had a negative operating cash flow in the past year.
KMTS Yearly Net Income VS EBIT VS OCF VS FCFKMTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • KMTS has a Return On Assets of -56.26%. This is in the lower half of the industry: KMTS underperforms 67.74% of its industry peers.
  • KMTS has a Return On Equity (-84.59%) which is in line with its industry peers.
Industry RankSector Rank
ROA -56.26%
ROE -84.59%
ROIC N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KMTS Yearly ROA, ROE, ROICKMTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • KMTS has a Gross Margin (46.40%) which is comparable to the rest of the industry.
  • KMTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KMTS Yearly Profit, Operating, Gross MarginsKMTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • KMTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • KMTS has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, KMTS has an improved debt to assets ratio.
KMTS Yearly Shares OutstandingKMTS Yearly Shares OutstandingYearly Shares Outstanding 2021 2023 2024 2025 10M 20M 30M 40M
KMTS Yearly Total Debt VS Total AssetsKMTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 6.52 indicates that KMTS is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.52, KMTS belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
  • A Debt/Equity ratio of 0.26 indicates that KMTS is not too dependend on debt financing.
  • KMTS has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: KMTS outperforms 54.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 6.52
ROIC/WACCN/A
WACC10.2%
KMTS Yearly LT Debt VS Equity VS FCFKMTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • KMTS has a Current Ratio of 5.47. This indicates that KMTS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.47, KMTS belongs to the top of the industry, outperforming 81.72% of the companies in the same industry.
  • A Quick Ratio of 5.47 indicates that KMTS has no problem at all paying its short term obligations.
  • KMTS has a better Quick ratio (5.47) than 83.87% of its industry peers.
Industry RankSector Rank
Current Ratio 5.47
Quick Ratio 5.47
KMTS Yearly Current Assets VS Current LiabilitesKMTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for KMTS have decreased strongly by -46.20% in the last year.
  • Looking at the last year, KMTS shows a very strong growth in Revenue. The Revenue has grown by 62.05%.
EPS 1Y (TTM)-46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.41%
Revenue 1Y (TTM)62.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.4%

3.2 Future

  • KMTS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.78% yearly.
  • KMTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.36% yearly.
EPS Next Y-15.99%
EPS Next 2Y-3.13%
EPS Next 3Y5.78%
EPS Next 5YN/A
Revenue Next Year56.17%
Revenue Next 2Y51.47%
Revenue Next 3Y48.49%
Revenue Next 5Y46.36%

3.3 Evolution

KMTS Yearly Revenue VS EstimatesKMTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M 250M
KMTS Yearly EPS VS EstimatesKMTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • KMTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year KMTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KMTS Price Earnings VS Forward Price EarningsKMTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KMTS Per share dataKMTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.13%
EPS Next 3Y5.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • KMTS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KESTRA MEDICAL TECHNOLOGIES

NASDAQ:KMTS (2/6/2026, 4:30:02 PM)

After market: 25.47 0 (0%)

25.47

+0.35 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-11
Earnings (Next)04-14
Inst Owners38.32%
Inst Owner ChangeN/A
Ins Owners0.99%
Ins Owner Change5.15%
Market Cap1.46B
Revenue(TTM)74.26M
Net Income(TTM)-138.79M
Analysts86.15
Price Target30.02 (17.86%)
Short Float %8.32%
Short Ratio6.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.12%
Min EPS beat(2)-5.83%
Max EPS beat(2)42.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.55%
Min Revenue beat(2)6.25%
Max Revenue beat(2)6.85%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.98%
PT rev (3m)8.33%
EPS NQ rev (1m)0.24%
EPS NQ rev (3m)-2.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.26%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)2.77%
Revenue NY rev (1m)0.41%
Revenue NY rev (3m)3.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.67
P/FCF N/A
P/OCF N/A
P/B 8.9
P/tB 8.9
EV/EBITDA N/A
EPS(TTM)-2.76
EYN/A
EPS(NY)-2.16
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS1.29
BVpS2.86
TBVpS2.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.26%
ROE -84.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.4%
FCFM N/A
ROA(3y)-162.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 330.87%
Cap/Sales 36.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.47
Quick Ratio 5.47
Altman-Z 6.52
F-Score5
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)226.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)88.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.41%
EPS Next Y-15.99%
EPS Next 2Y-3.13%
EPS Next 3Y5.78%
EPS Next 5YN/A
Revenue 1Y (TTM)62.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%53.4%
Revenue Next Year56.17%
Revenue Next 2Y51.47%
Revenue Next 3Y48.49%
Revenue Next 5Y46.36%
EBIT growth 1Y-66.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.7%
EBIT Next 3Y15.34%
EBIT Next 5YN/A
FCF growth 1Y-19.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.44%
OCF growth 3YN/A
OCF growth 5YN/A

KESTRA MEDICAL TECHNOLOGIES / KMTS FAQ

What is the ChartMill fundamental rating of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to KMTS.


What is the valuation status of KESTRA MEDICAL TECHNOLOGIES (KMTS) stock?

ChartMill assigns a valuation rating of 0 / 10 to KESTRA MEDICAL TECHNOLOGIES (KMTS). This can be considered as Overvalued.


What is the profitability of KMTS stock?

KESTRA MEDICAL TECHNOLOGIES (KMTS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for KESTRA MEDICAL TECHNOLOGIES?

The Earnings per Share (EPS) of KESTRA MEDICAL TECHNOLOGIES (KMTS) is expected to decline by -15.99% in the next year.